miR‐33 in cardiometabolic diseases: lessons learned from novel animal models and approaches
Abstract miRNAs have emerged as critical regulators of nearly all biologic processes and important therapeutic targets for numerous diseases. However, despite the tremendous progress that has been made in this field, many misconceptions remain among much of the broader scientific community about the...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Springer Nature
2021-05-01
|
| Series: | EMBO Molecular Medicine |
| Subjects: | |
| Online Access: | https://doi.org/10.15252/emmm.202012606 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849331936323960832 |
|---|---|
| author | Nathan L Price Leigh Goedeke Yajaira Suárez Carlos Fernández‐Hernando |
| author_facet | Nathan L Price Leigh Goedeke Yajaira Suárez Carlos Fernández‐Hernando |
| author_sort | Nathan L Price |
| collection | DOAJ |
| description | Abstract miRNAs have emerged as critical regulators of nearly all biologic processes and important therapeutic targets for numerous diseases. However, despite the tremendous progress that has been made in this field, many misconceptions remain among much of the broader scientific community about the manner in which miRNAs function. In this review, we focus on miR‐33, one of the most extensively studied miRNAs, as an example, to highlight many of the advances that have been made in the miRNA field and the hurdles that must be cleared to promote the development of miRNA‐based therapies. We discuss how the generation of novel animal models and newly developed experimental techniques helped to elucidate the specialized roles of miR‐33 within different tissues and begin to define the specific mechanisms by which miR‐33 contributes to cardiometabolic diseases including obesity and atherosclerosis. This review will summarize what is known about miR‐33 and highlight common obstacles in the miRNA field and then describe recent advances and approaches that have allowed researchers to provide a more complete picture of the specific functions of this miRNA. |
| format | Article |
| id | doaj-art-f9de2e4064ff4f6b9075aa00a4d61d3c |
| institution | Kabale University |
| issn | 1757-4676 1757-4684 |
| language | English |
| publishDate | 2021-05-01 |
| publisher | Springer Nature |
| record_format | Article |
| series | EMBO Molecular Medicine |
| spelling | doaj-art-f9de2e4064ff4f6b9075aa00a4d61d3c2025-08-20T03:46:21ZengSpringer NatureEMBO Molecular Medicine1757-46761757-46842021-05-0113511410.15252/emmm.202012606miR‐33 in cardiometabolic diseases: lessons learned from novel animal models and approachesNathan L Price0Leigh Goedeke1Yajaira Suárez2Carlos Fernández‐Hernando3Vascular Biology and Therapeutics Program, Yale University School of MedicineDepartment of Internal Medicine, Yale University School of MedicineVascular Biology and Therapeutics Program, Yale University School of MedicineVascular Biology and Therapeutics Program, Yale University School of MedicineAbstract miRNAs have emerged as critical regulators of nearly all biologic processes and important therapeutic targets for numerous diseases. However, despite the tremendous progress that has been made in this field, many misconceptions remain among much of the broader scientific community about the manner in which miRNAs function. In this review, we focus on miR‐33, one of the most extensively studied miRNAs, as an example, to highlight many of the advances that have been made in the miRNA field and the hurdles that must be cleared to promote the development of miRNA‐based therapies. We discuss how the generation of novel animal models and newly developed experimental techniques helped to elucidate the specialized roles of miR‐33 within different tissues and begin to define the specific mechanisms by which miR‐33 contributes to cardiometabolic diseases including obesity and atherosclerosis. This review will summarize what is known about miR‐33 and highlight common obstacles in the miRNA field and then describe recent advances and approaches that have allowed researchers to provide a more complete picture of the specific functions of this miRNA.https://doi.org/10.15252/emmm.202012606atherosclerosismetabolismmiR‐33miRNA |
| spellingShingle | Nathan L Price Leigh Goedeke Yajaira Suárez Carlos Fernández‐Hernando miR‐33 in cardiometabolic diseases: lessons learned from novel animal models and approaches EMBO Molecular Medicine atherosclerosis metabolism miR‐33 miRNA |
| title | miR‐33 in cardiometabolic diseases: lessons learned from novel animal models and approaches |
| title_full | miR‐33 in cardiometabolic diseases: lessons learned from novel animal models and approaches |
| title_fullStr | miR‐33 in cardiometabolic diseases: lessons learned from novel animal models and approaches |
| title_full_unstemmed | miR‐33 in cardiometabolic diseases: lessons learned from novel animal models and approaches |
| title_short | miR‐33 in cardiometabolic diseases: lessons learned from novel animal models and approaches |
| title_sort | mir 33 in cardiometabolic diseases lessons learned from novel animal models and approaches |
| topic | atherosclerosis metabolism miR‐33 miRNA |
| url | https://doi.org/10.15252/emmm.202012606 |
| work_keys_str_mv | AT nathanlprice mir33incardiometabolicdiseaseslessonslearnedfromnovelanimalmodelsandapproaches AT leighgoedeke mir33incardiometabolicdiseaseslessonslearnedfromnovelanimalmodelsandapproaches AT yajairasuarez mir33incardiometabolicdiseaseslessonslearnedfromnovelanimalmodelsandapproaches AT carlosfernandezhernando mir33incardiometabolicdiseaseslessonslearnedfromnovelanimalmodelsandapproaches |